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AbsTrACT
Objectives to characterise the sketetal muscle 
metabolic phenotype during early critical illness.
Methods Vastus lateralis muscle biopsies and serum 
samples (days 1 and 7) were obtained from 63 intensive 
care patients (59% male, 54.7±18.0 years, acute 
Physiology and chronic Health evaluation ii score 
23.5±6.5).
Measurements and main results From day 1 to 7, 
there was a reduction in mitochondrial beta-oxidation 
enzyme concentrations, mitochondrial biogenesis markers 
(Pgc1α messenger mrna expression (−27.4cn (95% ci 
−123.9 to 14.3); n=23; p=0.025) and mitochondrial 
Dna copy number (−1859cn (iQr −5557–1325); 
n=35; p=0.032). intramuscular atP content was 
reduced compared tocompared with controls on day 1 
(17.7mmol/kg /dry weight (dw) (95% ci 15.3 to 20.0) 
vs. 21.7 mmol/kg /dw (95% ci 20.4 to 22.9); p<0.001) 
and decreased over 7 days (−4.8 mmol/kg dw (iQr 
−8.0–1.2); n=33; p=0.001). in addition, the ratio of 
phosphorylated:total aMP-K (the bioenergetic sensor) 
increased (0.52 (iQr −0.09–2.6); n=31; p<0.001). 
there was an increase in intramuscular phosphocholine 
(847.2aU (iQr 232.5–1672); n=15; p=0.022), 
intramuscular tumour necrosis factor receptor 1 (0.66 µg 
(iQr −0.44–3.33); n=29; p=0.041) and il-10 (13.6 ng 
(iQr 3.4–39.0); n=29; p=0.004). Serum adiponectin 
(10.3 µg (95% ci 6.8 to 13.7); p<0.001) and ghrelin 
(16.0 ng/ml (iQr −7–100); p=0.028) increased. network 
analysis revealed a close and direct relationship between 
bioenergetic impairment and reduction in muscle mass 
and between intramuscular inflammation and impaired 
anabolic signaling. atP content and muscle mass were 
unrelated to lipids delivered.
Conclusions Decreased mitochondrial biogenesis and 
dysregulated lipid oxidation contribute to compromised 
skeletal muscle bioenergetic status. in addition, 
intramuscular inflammation was associated with 
impaired anabolic recovery with lipid delivery observed as 
bioenergetically inert. Future clinical work will focus on 
these key areas to ameliorate acute skeletal muscle wasting.
Trial registration number nct01106300.
InTrOduCTIOn
Acute skeletal muscle wasting occurs early and 
rapidly in critical illness1 and is reported to be a 
major driver of long-term disability.2 Indeed, 
muscle wasting is associated with increased length 
of intensive care unit (ICU) stay,1 hospital stay1 
and mortality.3 It is underpinned by a fall in muscle 
protein synthesis,1 a process which, in healthy 
individuals, is responsive to exercise and amino 
acid loading.4 However, clinical trials of enhanced 
nutritional support5–8 and early exercise training9–12 
in acute critical illness have yielded inconsistent 
results in terms of amelioration of muscle wasting 
and improvement in physical function.
Muscle protein synthesis is ATP depen-
dent.13 14 The observed reduction in early critical 
illness15 16 may be the result of decreased mitochon-
drial number or function, or both.15 16 These defects 
of metabolism may be the result of decreased 
substrate utilisation including glucose, a well-rec-
ognised complication of critical illness. Further-
more, the metabolic anomalies observed could be 
Key messages
What is the key question?
 ► To investigate if ATP bioavailability and lipid 
metabolism are drivers of the early and rapidly 
acute skeletal muscle wasting that occurs 
during critical illness.
What is the bottom line?
 ► In this first study to investigate the relationship 
between bioenergetics changes and skeletal 
muscle wasting during early critical illness, 
alterations in fat metabolism and ATP 
abundance are associated with the severity of 
inflammation and altered oxygen signalling, 
which could be considered as targets for future 
therapies.
Why read on?
 ► Skeletal muscle wasting in critical care is 
associated with impaired lipid oxidation 
and reduced ATP bioavailability, driven by 
intramuscular inflammation and altered 
hypoxic signalling, which may account for the 
inconsistent outcome observed in the nutrition 
and exercise clinical trials.
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Critical care
the consequence of the decreased utilisation of other energy 
substrates, such as fatty acids. This may, in part, account for the 
failure to show benefit in the previous nutrition and exercise 
clinical trials.5–12 17
Systemic hypoxia and inflammation are part of the phenotype 
of critical illness18–20 and both can impair mitochondrial func-
tion16 and muscle protein synthesis.21 22 These interactions are 
complex23 and, as yet, incompletely elucidated with limited data 
available reporting the relationship between loss in muscle mass 
and skeletal muscle hypoxia and inflammation.
While mitochondrial dysfunction has reported,15 16 24 these 
data have not investigated the relationship with skeletal muscle 
wasting and muscle protein turnover. We investigated the rela-
tionships between loss in muscle mass in early critical illness and 
skeletal muscle inflammatory, hypoxic and protein homeostatic 
signalling together with the bioenergetic status.
MeThOds
Patients were those enrolled in the previously described MUSCLE 
study (NCT01106300, www. clinicaltrials. gov).1 At enrolment, 
written assent was obtained from the next of kin with retro-
spective patient consent obtained when full mental capacity was 
regained.
Patients were recruited within 24 hours of admission to a 
university hospital and a community hospital ICU. All were 
anticipated to be invasively ventilated for >48 hours and to 
spend >7 days in, and survive, ICU. Patients were excluded 
if these criteria were not met and if they were pregnant or a 
lower limb amputee, or suffering primary neuromuscular disease 
or disseminated cancer. Vastus lateralis biopsies (days 1 and 7) 
were performed and snap-frozen in under 10 s. Serum samples 
(days 1, 3, 7 and 10) and physiological data were collected as 
described.1
Mitochondrial components
Electron transport chain component protein concentrations 
were determined, as were those of key enzymes of fatty acid 
transport (carnitine palmitoyltransferase-1), beta-oxidation 
(medium chain acyl-CoA dehydrogenase) and oxidation of 
unsaturated fatty acids (2,4-dienoyl-CoA reductase 1) using 
muscle homogenates (Luminex technology; FLEXMAP 3D, 
Merck Millipore; online supplementary table S1). The peroxi-
somal beta-oxidation enzyme multifunctional enzyme-2 was 
quantified as was the electron transport system electron carrier 
electron transferring flavoprotein.
bioenergetic quantification
Intramuscular ATP, free creatine and phosphocreatine levels 
were fluorometrically measured.25 These were compared against 
unpublished data from 31 healthy subjects comprising both 
those with and without stable chronic disease, as per our patient 
cohort (online supplementary table S7). Intracellular energy 
sensor AMP-K protein concentration was measured by using 
western blot analysis.
Muscle metabotyping
Thawed muscle tissues underwent extraction and the organic 
phase was used for ultra performance liquid chromatography 
and tandem mass spectrometry optimised for lipid profiling as 
previously described.26
Mitochondrial biogenesis
Mitochondrial DNA copy number (CN) and messenger 
RNA (mRNA) expression of members of the peroxisome 
proliferator-activated receptor gamma coactivator 1 family 
(PGC1α, PG1β and PPRC-1, central regulators of mitochondrial 
metabolism and biogenesis27) were independently quantified 
(quantitative PCR: qStandard, London, UK; online supplemen-
tary table S2) and reported as normalised CN. Expression of 
dynamin-related protein 1 (DRP-1; a marker of mitochondrial 
fission28) was determined.
Adipokine and ghrelin response
ELISA (Merck Millipore; online supplementary table S3) of 
serum ghrelin and adipokinin concentrations was performed.
Intramuscular hypoxia and inflammation
We measured intramuscular concentrations of hypoxia-induc-
ible factor 1 alpha (HIF-1α, the primary hypoxia-induced tran-
scription factor) (Luminex technology; FLEXMAP 3D) and 
pro-inflammatory/anti-inflammatory cytokines (high-sensitivity 
evidence investigator chip array, Randox Antrim).
statistical analysis
Data were assessed for normality (D’Agostino-Pearson omnibus 
test), and analysed using Student’s t-test, Pearson’s coefficient, 
Mann-Whitney U test and Wilcoxon’s signed rank tests as appro-
priate. Parametric data are reported as mean (CIs) and non-para-
metric as median (IQR).
Metabotyping
Two forms of data reduction (principal components analysis 
and partial least squares discriminant analysis) were used for 
visualisation of untargeted profiling data. Principal component 
analysis (LCMS data) visualised inherent clustering and iden-
tified outliers. Partial least squares discriminant analysis was 
performed to maximise class differences between day 1 and day 
7 samples while minimising variability unrelated to class. These 
were used to identify metabolites whose concentration was 
different between day 1 and day 7 and thus determine metab-
olites of importance. These were then presented as raw data to 
confirm the changes identified in the multivariate methods.
Network analysis
Each variable was represented as a node, and edges weighted 
by pairwise Pearson's correlation coefficient (threshold r>0.4). 
Temporal changes (change from day 1 to day 7) in concentra-
tions of active moieties of the anabolic/catabolic signalling path-
ways, physiological and nutritional data and muscle mass were 
included.1 Clinical variables include were those of statistical 
significance in our previously published multivariate analysis.1 
McClust29 was implemented in Cytoscape (www. cytoscape. 
com)30 to reveal complex relationships otherwise hidden. As in 
all network analyses, multiple comparison were not corrected 
for as p values were not determined.31
See online supplementary file for further methodological 
details.
resulTs
The characteristics of the cohort have been previously 
described.1 Of the 91 patients recruited, 63 fulfilled criteria for 
longitudinal analysis. Serial vastus lateralis biopsy samples were 
available from 33 patients and serum for 59, and metabotyping 
performed on a subcohort of 15 (online supplementary figure 
S1). The characteristics of the whole cohort, patients biopsied 
and those metabotyped did not differ (all p>0.05), except that 
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the proportion of males was higher among those metabotyped 
(80.0% vs 58.7%; p=0.047) (table 1).
Mitochondrial components
No change was observed in individual mitochondrial respira-
tory complex protein concentrations between day 1 and day 7 
(all p>0.050, online supplementary figure S2, table S4). Mito-
chondrial beta-oxidation enzyme concentrations decreased 
(all p<0.050, online supplementary figure S3, table S5), while 
concentrations of multifunctional enzyme-2 (extra-mitochon-
drial beta-oxidation) were unchanged (p=0.666).
bioenergetic data
Intramuscular ATP content on day 1 in critically ill patients was 
lower than that of healthy subjects (17.7 mmol/kg dry weight 
(dw) (95% CI 15.3 to 20.0) vs 21.7 mmol/kg dw (95% CI 20.4 
to 22.9); p=0.005) (figure 1A). Day 1 ATP content was lower in 
critically ill patients with chronic disease than in those without 
(13.61 mmol/kg dw (95% CI. 9.9 to 17.4) vs 21.26 mmol/kg 
dw (95%CI 19.0 to 23.6); p=0.001, figure 1A). Correspond-
ingly, ATP content on day 1 was similar in healthy individuals 
and critically ill patients without chronic diseases (22.17 mmol/
kg dw (95% CI 20.7 to 23.7) vs (21.26 mmol/kg dw (95% CI 
18.9 to 23.6); p=0.383). However, critically ill patients with 
pre-existing chronic disease had lower ATP content on day 1 
than ambulant COPD controls (13.6 mmol/kg dw (95% CI 9.9 
to 17.4) vs 21.1 mmol/kg dw (95% CI 19.0 to 23.2); p<0.001).
ATP content declined from day 1 to day 7 in the whole cohort 
(−4.8 mmol/kg  dw  (IQR  −8.0–1.2);  n=33;  p=0.001).  The 
difference between those with and without pre-existing chronic 
diseases persisted at day 7 (10.43 mmol/kg dw (95% CI 7.3 to 
13.5) vs 16.47 mmol/kg dw (95% CI 14.2 to 18.8), respectively; 
p=0.002), although ATP content change over 7 days was no 
different between those with and without pre-existing chronic 
diseases  (−3.18%  (95%CI −8.1  to  1.7)  vs −4.79%  (95% CI 
−6.8 to −2.8); p=0.503). The ratio of phosphorylated to total 
AMP-K rose from day 1 to day 7 in the critically ill cohort (0.88 
(IQR 0.62–2.52) vs 1.57 (IQR 0.68–3.99); n=31; p<0.001) 
(figure 1B; online supplementary table S7).
Phosphocreatine concentration was also lower in patients than 
in healthy subjects on day 1 (41.7 mmol/kg dw (95% CI 32.6 to 
50.4) vs 72.7 mmol/kg dw (95% CI 69.0 to 76.4); p<0.001) and 
declined over the following 7 days (−14.7 mmol/kg dw (95% CI 
−23.3  to −6.1);  n=33;  p=0.039)  (figure 1C). Total creatine 
content was similar to that found in healthy subjects at day 1 
(116.9 mmol/kg dw (95% CI 105.7 to 128.0 vs 126.0 mmol/kg 
dw (95% CI 120.7 to 131.2); p=0.142 (figure 1D), but declined 
over  7  days  (−25.39 mmol/kg  dw  (IQR −42.4–1.44);  n=33; 
p<0.048). Phosphocreatine and total creatine content were 
independent of chronic disease status.
Metabotyping
A two-component cross-validated model had an R2Y of 0.72 and 
Q2 of 0.41 and area under the receiver operating characteristic 
of 0.95 for predicting day of muscle sampling. Following correc-
tion for multiple comparisons, a decrease in an intramuscular 
triglyceride(TG(12:0/13:0/22:0);  −1366AU  (95%  CI  −2605 
to  −127);  n=15;  p=0.048)  and  an  increase  in  several  intra-
muscular phosphocholine ((representative example PC (41:0)); 
847.2AU (IQR 232.5–1672); n=15; p=0.022) over 7 days 
retained statistical significance (figure 2; online supplementary 
table S6).
Mitochondrial biogenesis
PGC1α  mRNA  expression  decreased  (−27.4CN  (95% CI 
−123.9  to  14.3);  n=23;  p=0.025)  between  day  1  and  day  7 
as did that of the marker of mitochondrial fission DRP-1 
(−42.7CN  (95% CI  −77.2  to  8.2);  n=23;  p=0.018,  online 
supplementary figure S4, table S6). Mitochondrial DNA CN also 
decreased over the first 7 days (−1859CN (IQR −5557–1325); 
n=35; p=0.032). No change was observed in PGC1β or PPRC1 
expression over 7 days (both p>0.05).
Adipokine and ghrelin response
Serum adiponectin concentration increased from day 1 to day 
7 (10.3 μg (95% CI 6.8 to 13.7); n=59; p<0.001), as did those 
of ghrelin (16.0 ng/mL (IQR −7–100); n=59; p=0.028, online 
supplementary table S8). Both increases were sustained at day 
10.  Resistin  concentration  was  unchanged  (−0.75 µg (95% CI 
−1.6  to  0.1);  n=59;  p=0.918),  as  was  leptin  concentration 
(−0.01; n=59; p=0.113). In the obese subgroup (n=16, body 
mass  index  ≥30 kg/m2), leptin levels decreased over 10 days 
(26.6 ng/mL (95% CI 22.7 to 30.5) to 19.2 ng/mL (95% CI 13.6 
to 24.8); n=16; p=0.048).
hypoxic and inflammatory signalling
Intramuscular HIF-1α protein concentration increased from 
day  1  to  day  7  (−12.0AU  (IQR  2.3–47.8);  n=33;  p<0.001) 
(figure 3C). Change in HIF-1α was unrelated to changes in the 
PaO2 of oxygen in arterial blood, or to the saturation of arterial 
haemoglobin with oxygen (both r2<0.1, p>0.10; online supple-
mentary table S9).
Intramuscular tumour necrosis factor receptor 1 concentra-
tion increased from day 1 to day 7 (0.66 μg (IQR −0.44–3.33); 
n=29; p=0.041 (figure 3A), as did intramuscular interleukin 
(IL)-10 concentration (13.6 ng (IQR 3.4–39.0); n=29; p=0.004 
(figure 3B). Intramuscular concentrations of IL-1α, IL-1β, IL-2, 
IL-4, IL-6, IL-8, tumour necrosis factor-alpha, TNFR2, interfer-
on-gamma, monocyte chemoattractant protein 1 and endothe-
lial growth Factor did not change over 7 days (n=29; p>0.05; 
table 2, figure 3A,B,D).
Integration of data: network analysis
While simple linear regression analyses did not provide useful 
insight (online supplementary table S8, S12-14), nine data 
clusters were delineated, comprising 91 different interactions 
between longitudinal data from clinical, protein homeostatic, 
inflammatory, mitochondrial, bioenergetic and nutritional data 
(figure 4). Of these, 79 (87%) interactions have been observed 
previously in human tissue, and the remainder in animal tissue 
(online supplementary table S10-12), further validating our 
approach. The network revealed the close relationship between 
bioenergetic impairment and reductions in both rectus femoris 
cross-sectional area and protein/DNA ratio (figure 4A), and 
between intramuscular inflammation and impaired anabolic 
signalling (figure 4B). Bioenergetic impairment and fall in muscle 
mass appeared unrelated to the delivery of phospholipids, or 
of saturated, monounsaturated or polyunsaturated fatty acids, 
delivered (figure 4C).
Further results are available in the online supplementary file.
dIsCussIOn
In this study of patients during early critical illness, we report 
novel data detailing the the relationships between skeletal muscle 
wasting and the inflammatory, hypoxic and protein homeostatic 
signalling together with the bioenergetic status of the muscle. A 
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Table 1 Baseline characteristics of patients
Characteristics All patients Intramuscular bioenergetic data lipidomics
N 63 33 15
Age 54.5 (50.0–59.1) 54.6 (37.5–62.0) 57.4 (49.2–65.7)
Male sex—n (%)* 37 (58.7) 24 (72.7) 12 (80.0)†
Pre-ICU LOS-days‡ 1 (1–45) 1 (1–36) 1 (1–6)
Days ventilated‡ 10 (2–62) 8 (2–62) 7 (2–23)
ICU LOS-days‡ 16 (6–80) 16 (7–80) 16 (6–20)
Hospital LOS-days‡ 30 (10–334) 30 (11–212) 38 (10–141)
APACHE II score 23.5 (21.9–25.2) 22.6 (20.1–25.0) 23.3 (19.3–27.3)
SAPS II score 45.5 (41.8–49.3) 44.2 (39.4–49.0) 44 (38.1–50.0)
ICU survival—n (%)* 61 (97) 31 (94) 14 (93)
Hospital survival— n (%)* 56 (89) 28 (84.8) 13 (87)
Renal replacement therapy—n (%) 19 (30.2) 10 (30.3) 4 (28.6)
Days NMBA use‡ 0 (0–6) 0 (0–6) 0 (0–2)
Hydrocortisone dose (mg)§‡
Day 1 0 (0–800) 0 (0–800) 0 (0–800)
Total by day 10 0 (0–4533) 0 (0–4533) 266.5 (0–4533)
HMG-CoAreductase inhibitor use—n (%) 11 (17.4) 5 (15.2) 2 (14.3)
Blood glucose (mmol/L)‡ 7.4 (5.1–11.4) 7.5 (7.1–7.9) 7.5 (6.9–8.1)
Cumulative insulin (IU)‡ 93 (0–1704.0) 103.9 (0–30.5) 32.9 (0–11.6)
Protein delivered (g/kg ibw) 6.7 (5.3–8.2) 5.4 (4.5–6.2) 5.3 (3.8–6.7)
Energy delivered (kcal/kg ibw) 158.4 (143.9–172.9) 148.4 (126.0–170.8) 159.5 (122.0–197.0)
Fat delivered (g/kg ibw)‡ 4.87 (4.1–5.6) 4.55 (3.7–5.4) 5.95 (3.3–8.6)
Cumulative propofol (mg) 8684 (6320–11 048) 10 825 (6619–15 030) 7590 (2264–12 916)
Admission RFCSA (mm2) 500.6 (448.5–552.8) 511.6 (435.8–587.4) 551.8 (441.9–661.7)
Admission diagnosis—n (%) 31 (49.2) 14 (42.4) 7 (46.7)
Sepsis 16 (25.4) 12 (36.3) 4 (26.7)
Trauma 5 (7.9) 4 (12.1) 2 (13.3)
Intracranial bleed 5 (8.0) 1 (3.0) 1 (6.7)
Acute liver failure 6 (9.5) 2 (6.1) 1 (6.7)
Cardiogenic shock
Comorbidities—n (%)
COPD 9 (14.3) 6 (18.2) 3 (20.0)
Ischaemic heart disease 10 (15.9) 5 (15.2) 2 (13.3)
Hypertension 13 (19.0) 5 (15.2) 2 (13.3)
Diabetes mellitus 8 (12.7) 3 (9.1) 0 (0.0)
Liver cirrhosis 6 (9.5) 3 (9.1) 2 (13.3)
Chronic pancreatitis 2 (3.2) 1 (3.0) 0 (0.0)
Haematological disease 4 (6.3) 2 (6.1) 1 (6.7)
Obesity 3 (4.8) 0 (0.0) 2 (13.3)
Previous CVA 1 (1.6) 1 (3.0) 0 (0.0)
Renal impairment 2 (1.6) 1 (3.0) 1 (6.7)
Crohn’s disease 1 (1.6) 0 (0.0) 0 (0.0)
Thyroid disease 3 (4.8) 1 (3.0) 1 (6.7)
Data are mean values (95% CIs). Student’s t-test was used except for male sex and ICU survivals. 
*Χ2test was used. 
†Indicates median with range. Mann-Whitney U test was used.-
‡Indicates p < 0.05 when compared with whole cohort.
§Corticosteroid dosing as hydrocortisone equivalents. 
APACHE II, Acute Physiology and Chronic Health Evaluation score; CVA, cerebrovascular accident; ibw, ideal body weight; HMG-CoA, hICU, intensive care unit; LOS, length of stay; 
NMBA, neuromuscular blocking agents; RFCSA, admission rectus femoris cross-sectional area; SAPS II, Simplified Acute Physiology Score.
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network analysis has been used to describe these relationships in 
the context of clinical physiological data. Three important novel 
findings were observed: i) decreased ATP, creatine and phos-
phocreatine availability are closely and directly related to acute 
skeletal muscle wasting (protein/DNA ratio and rectus femoris 
cross-sectional area); ii) activation of hypoxic and inflamma-
tory signalling are closely and directly related to impairment of 
anabolic signalling pathways and iii) changes in intramuscular 
ATP content and skeletal muscle mass are unrelated to the quan-
tity of lipids delivered.
Change in bioenergetic state during early critical illness
Decreases in PGC1α, markers of mitochondrial fission (DRP-1) 
and mitochondrial DNA CN reflect reduced mitochondrial 
biogenesis. Mitochondrial complex concentrations did not change 
over the first week of critical illness, although mitochondrial 
beta-oxidation enzyme concentrations fell. Although functional 
mitochondrial measurements could not be performed, decreases 
in beta-oxidation and oxidative phosphorylation explain the 
finding that myocellular ATP content was lower in patients than 
in healthy controls on day 1, and decreased further over the first 
week. The measured decrease in muscle ATP, along with phospho-
creatine and creatine content was accompanied by an increase in 
AMP-K, implying a compromised bioenergetic state and poten-
tially decreasing anabolism. Assimilating previously published 
data on muscle mass and protein homeostasis regulation,1 network 
analysis confirmed the relationship between impaired bioener-
getic status, bioenergetic sensing signal and loss in muscle mass.
Figure 1 Bioenergetic data. (A) Skeletal muscle ATP in control subjects and on day 1 and day 7 of critical illness. (B) Ratio of phosphorylated to total 
AMP-K on day 1 and day 7 of critical illness. (C) Phosphocreatine and (D) total creatine data in control subjects and on day 1 and day 7 of critical 
illness. Clear symbols represent patients with stable pre-existing chronic disease, while filled symbols represent patients without pre-existing chronic 
disease. Red lines represent mean and 95% CI. *P<0.05 for comparisons between time points (horizontal parentheses) and comparisons between 
those with and without pre-existing chronic diseases (vertical parentheses). dw, dry weight.
Figure 2 Ultra performance liquid chromatography mass spectrometry data for muscle samples on day 1 and day 7 of critical illness. (A) 
Phosphocholine and (B) triglyceride. *P<0.05.
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Neither muscle ATP content nor muscle mass was related 
to the quantity of fatty acids delivered as part of nutrition or 
sedative use. This was in keeping with both the measurements 
of lipid oxidation performed, and the increase in myocellular 
phosphocholine in a separate analysis. These data suggest that 
current critical care nutritional management is unable to prevent 
development of an impaired bioenergetics status, which may be 
causal in regard to acute muscle wasting.
Metabolo-inflammatory response during early critical illness
The complex relationship between inflammation, anabolism 
and metabolism was demonstrated in the network analysis and 
may impact on both skeletal muscle mass and quality. Intramus-
cular inflammatory mediators clustered with anabolic signal-
ling proteins, suggesting a deleterious effect of inflammation. 
Previous work by Constantin et al32 demonstrated anabolic 
signalling transcription upregulation with no corresponding 
increase in protein expression. Inflammatory signalling likely 
inhibits this translation of programmed anabolic restoration32 
and therefore muscle mass maintenance and has been demon-
strated in animal models.22 33
Myonecrosis with an associated macrophagic infiltrate has 
also been reported.34 Elevated intramuscular IL-10 as seen in 
these data may activate macrophages35 and induce phagocytosis 
of myofibre debris, and represent another potential mechanism 
of switching in macrophage phenotype.35 This may counteract 
the detrimental effects of the observed lipid accumulation, 
which may affect switching from the M1 (pro-inflammatory) 
to M2 (anti-inflammatory) macrophage phenotype,36 impeding 
autophagy37 and recovery from myonecrosis. In addition, IL-10 
demonstrates a suppressive effect on the Th1 cytokine response 
in injured muscle, that is, decreasing the inflammatory effects 
of M1-associated effectors, such as IL-638 and TNF-α.39 The 
final macrophage phenotype remains unclear but is likely to be 
Figure 3 Change in intramuscular cytokine concentration between day 1 and day 7 of critical illness. (A) TNF-α, tumour necrosis factor alpha; 
TNFR1, tumour necrosis factor receptor 1; TNFR2, tumour necrosis factor receptor 2; (B) IL-4, interleukin-4, IL-10, interleukin-10; (C) HIF-1α, hypoxia-
inducible factor 1 alpha; (D) IL-1α, interleukin-1 alpha; IL-1β, interleukin-1 beta; IL-6, interleukin-6; IFN-γ, interferon-gamma; EGF, epithelial growth 
factor. *P<0.05.
Table 2 Intramuscular cytokine concentrations on day 1 and day 7 of 
critical illness (n=29)
Cytokine day 1 day 7 P values
TNF-α 11.2 (0.6–32.0) 0.6 (0.6–24.0) 0.375
TNFR1 0.34 (0.0–1.5) 1.1 (0.0–3.5) 0.042*
TNFR2 0.01 (0.01–1.1) 1.4 (0.01–2.7) 0.083
IL-1α 6.8 (5.2–9.8) 7.6 (6.4–10.2) 0.715
HIF-1α 14.0 (9.8–22.5) 26.0 (21.0–69.8) <0.001*
IL-1β 28.4 (21.6–44.0) 30.8 (27.2–37.2) 0.229
IL-2 51.2 (0.9–66.0) 48.8 (0.9–56.8) 0.294
IL-4 150.0 (88.6–370.0) 242.0 (152.2–719.4) 0.206
IL-6 19.2 (6.8–59.8) 37.2 (12.2–84.2) 0.495
IL-8 21.6 (7.4–58.2) 52.8 (10.6–177.0) 0.100
IL-10 11.2 (0.37–41.8) 24.8 (14.8–298.4) 0.005*
IFN-γ 6.8 (0.4–8.8) 8.4 (3.0–9.2) 0.353
MCP-1 84.8 (18.1–122.2) 116.0 (88.4–267.2) 0.168
EGF 22.8 (2.0–40.6) 21.2 (1.0–29.6) 0.301
Data are median (IQR). All units are in ng/L except TNFR1 and TNFR1 (μg/L) and 
HIF-1α (Median Florescence Index).
*P values are for two- tailed Student's t-test for parametric data and Wilcoxon rank 
test for non-parametric data. 
EGF, endothelial growth factor; IFN-γ, interferon-gamma; IL, interleukin; MCP-1, 
monocyte chemoattractant protein-1; TNF-α, tumour necrosis factor alpha;  TNFR, 
tumour necrosis  factor receptor; VEGF, vascular endothelial  growth factor.
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the result of a balance of these factors, which may be altered by 
interventions that either a) decrease inflammation or b) decrease 
lipid accumulation.
The rise in HIF-1α was unrelated to the presence of systemic 
hypoxia, although the presence of cellular dysoxia cannot be 
excluded. Measuring the totality of the balance between tissue 
oxygen supply and demand in muscle beds is not technically 
possible in the clinical context. Nor is it easy to separate the 
extent to which metabolic change is dependent or consequent 
to altered oxygen or substrate delivery. However, HIF activity 
can be stimulated via pro-inflammatory cytokines,40 circulating 
lactate41 or insulin resistance.42 Thus, the HIF-1α signalling in 
muscle during critical illness appears to mirror the complex 
relationship between hypoxic signalling and inflammation 
seen in solid tumours.23 Regardless, this increase in HIF-1α 
concentration may reflect alterations in glucose metabo-
lism such as the Pasteur effect,43 metabolic reprogramming to 
allow Glucose Transporter type-4 membrane translocation42 or 
attempts to stimulate glycolysis.43 Additional examination of the 
complexity of glucose metabolism was beyond the scope of this 
manuscript.
The rise in adiponectin could represent a homeostatic 
response to lipid accumulation and/or insulin resistance,44 and 
increasing ghrelin concentrations may reflect the compromised 
bioenergetics state in skeletal muscle. However, adiponectin and 
ghrelin also play a role in the regulation of inflammation,45 46 
and cluster analysis suggests a close relationship with the inflam-
matory response.
These data suggest that intramuscular inflammation is likely 
to prevent anabolic restoration, impeding the effects of exercise 
Figure 4 Multidimensional network analysis of components of bioenergetics status, hypoxia and inflammatory signalling, protein homeostasis 
signalling molecules, measures of muscle mass, clinical physiology data and lipid and carbohydrate nutrition delivered. Data are change over 
7 days except for nutritional data (total delivered over 7 days) and organ failure (cumulative). Lines represent r values, green being positive and red 
negative, with greater thickness representing higher values. Panels represent Markov clusters: (A) measures of muscle mass and energetic data; 
(B) protein homeostasis and inflammation; (C) nutritional lipid delivery. AKT, protein kinase B; CPT, carnitine palmitoyltransferase-1; CRP, Creactive 
protein; DECR1,2,4 dienoyl-CoA reductase 1; DRP-1, dynamin-related protein 1; E4 BP1, eukaryotic initiation factor 4E binding protein 1; EGF, 
epithelial growth factor; ETF, electron transferring flavoprotein; FOXO, forkhead box class O-1; HCO3-, serum bicarbonate; HIF-1 α, hypoxia-inducible 
factor 1 alpha; IGF-1R, insulin-like growth factor-1; IFN- γ, interferon-gamma; IL, interleukin; MCAD, medium chain acyl-CoA dehydrogenase; MCP-1, 
macrophage chemotactic protein-1; MCT, medium chain triglycerides; mTOR, mammalian target of rapamycin; MUFA, monounsaturated fatty acids; 
MXN, mitochondrial copy number; OF, organ failure; P. lipid, phospholipids; P70S6 K, 70 kDa S6 protein kinase; PCR, phosphocreatine; P/D, protein-
to-DNA ratio; PS, polysaccharides; PUFA, polyunsaturated fatty acids; RFCSA, rectus femoris cross-sectional area; SFA, saturated fatty acids; TCR, 
total creatine; TNF-α, tumour necrosis factor alpha; TNFR1, tumour necrosis factor receptor 1; TNFR2, tumour necrosis factor receptor 2. 
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or amino acid supplementation on muscle protein synthesis. 
HIF-1α upregulation is associated with this inflammation and 
may modulate the metabolic response.
Clinical relevance
These data are the first to suggest that the lipid component of 
enteral and parenteral nutrition may be, in part, bioenergetically 
inert in the context of critical illness. This may be of substantial 
clinical importance, given that lipids contribute 29%–43%47 48 of 
the energy content in enteral, and 50% of parenteral, formulae.49 
These findings thus offer a plausible explanation for the apparent 
conflict between data from observational studies demonstrating 
a clinical benefit from increased nutrition over the entire ICU 
stay50 and the lack of benefit observed with early targeted nutri-
tion.5–7 In early critical illness, ATP turnover may not respond to 
higher calorific feed content and therefore differ little between 
intervention and usual care groups in clinical trials, particularly 
when parenteral nutrition is used.5 6 17
Likewise, a failure of ATP turnover may account for a limited 
response to (and thus the observed limited benefit from) exercise 
interventions9 10 12 with concomitant hypoxic21 and/or inflam-
matory stimuli additionally impairing muscle protein synthesis 
resulting in an attenuated response to intervention. However, as 
these adverse stimuli decrease with treatment and time, nutrition 
delivered may augment recovery.
Altering the composition of feed delivered in critical illness to 
exclude the lipid component may, in part, address the observed 
bioenergetic impairment and is an area for further research.
Future work
We consider that future clinical studies should be directed towards 
addressing these three core important novel findings. However, 
targeting a single molecule or other aspect of altered biology is 
unlikely to be successful. Interventions will likely need to target the 
whole, or multiple parts of the network (ie, the molecular signa-
ture), in the same fashion perhaps as asthma51 or breast cancer.52
From these data, we propose potential research to be targeted 
at: i) skeletal muscle wasting as a consequence of a reduction 
in ATP, creatine and phosphocreatine availability, for example, 
non-invasive diagnostic techniques to measure mitochondrial 
function; development of treatments to ameliorate mitochon-
drial dysfunction and/or skeletal muscle energy content including 
the use of supplemental creatine; ii) skeletal muscle anabolism, 
which is negatively affected by hypoxia and inflammation, 
for example, targeted anti-inflammatory treatments, which 
may be pharmacological, nutritional and exercise prescriptions; 
confirmation of timing for nutritional and exercise delivery to 
aid anabolic restoration; iii) lipid delivery, which has limited 
impact of skeletal muscle energy status, for example, the use 
of alternative non-fat fuel sources and removal of fatty acid 
supplementation.53
In addition, the low bioenergetic baseline of patients with 
pre-existing chronic diseases highlights the need for tailored 
interventions, including nutrition,50 and stratification in trials.54
limitations
We did not directly measure mitochondrial function in snap-
frozen samples, due to limitations in the validity of this 
approach.55 56 However, our focus was on the downstream 
effects of previously described alterations in mitochondrial func-
tion15 16 24 and both the fall in ATP and increases in phospholipids 
are in keeping with the static measurements performed. Tissue 
was rapidly acquired (under 10 s) and snap-frozen allowing 
further confidence in these data.57 Limited tissue availability 
precluded more granular metabophenotyping, although suffi-
cient to test the hypothesis. The consistent and marked declines 
in muscle ATP and the muscle creatine pool may be contributed 
to by muscle tissue necrosis that has been previously observed.1 
Total ghrelin was measured rather than active components such 
as acyl-ghrelin58 and may not reflect true activity. The network 
analysis allowed revelation of patterns of activity that would 
otherwise have been hidden by traditional analysis31 of a rela-
tively small (although deeply phenotyped) cohort, which never-
theless represents the largest longitudinal serial muscle biopsy 
cohort in acute critical illness. Ideally, these findings would be 
replicated in a second independent sample. Given the difficulties 
in performing serial muscle biopsies in the critically ill, this was 
considered beyond the scope of the study. Our data may not be 
generalisable to all critically ill patients, as this cohort consisted 
of patients of high acuity (Acute Physiology and Chronic Health 
Evaluation II score of 23.5 (95% CI 21.9 to 25.2), who spent a 
minimum of 7 days in critical care. A validation cohort of lesser 
acuity may offer differing results. The patient cohort is heteroge-
neous in many regards, as is typical of the critically ill. However 
we, and others, have demonstrated that similar of patterns exist 
in critically ill patients with respect to acute muscle wasting in 
terms of muscle mass1 59 and function,54 59 60 molecular biology1 
and in this current application, metabolism, despite heteroge-
neity in presenting disease. Moreover, the statistical approach 
used would reveal such heterogeneity if it existed. These data 
strongly support the presence of metabolic homogeneity. Of clin-
ical importance, the mechanisms identified were present across a 
mixed ICU population. It is, of course, possible that the balance 
of such elements may vary among individual patients (eg, with 
differing levels of inflammation, hypoxaemia, corticosteroid and 
vasopressor agent exposure).
Only 5.3% of data entered into the network analysis was 
missing, which is within acceptable missing data threshold.61 The 
convergence of data from separate laboratories and techniques 
also increases confidence in our conclusions. The first day of 
ICU admission does not necessarily reflect the first day of crit-
ical illness. While unable to quantify physiological derange-
ment prior to admission, the median time from hospital to ICU 
admission was only 24 hours. In addition 16/34 patients suffered 
major trauma or an intracranial bleed and were not exposed to 
antecedent decline. Due to the observational nature of our study, 
causal links in terms of mechanism cannot be made. While longi-
tudinal studies remain the focus of this work, we acknowledge 
the need for future work accounting for alterations in inflamma-
tion and hypoxia signalling relative to healthy controls.
All control muscle ATP, phosphocreatine and free creatine 
concentrations represent unpublished, archived, historical data 
that were generated prior to the analysis performed on muscle 
from critically ill patients. However, all measurements were stan-
dardised as they were performed in the same laboratory, using 
the same techniques by the same research group. Further control 
muscle ATP, creatine and phospocreatine contents are noted to 
be within normal range.25
Conclusions
These data have shown that there is a relationship between an 
impaired bioenergetic status and acute muscle wasting during 
early critical illness. This indeed may explain the reduced clinical 
effectiveness of the currently employed nutritional supplementa-
tion and exercise therapy interventions used in the ICU. Dysreg-
ulated lipid oxidation and decreased mitochondrial biogenesis 
contribute to this compromised skeletal muscle bioenergetic 
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status. In addition, intramuscular inflammation was associated 
with impaired anabolic recovery with lipid delivery during early 
critical illness observed as bioenergetically inert. Future clinical 
work will need to focus on these key areas to develop strategies to 
ameliorate acute acute skeletal muscle wasting during early critical 
illness.
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